German-based immuno-oncology company hires Dr Alfredo Zurlo
Glycotope, a clinical-stage immuno-oncology company built on glyco-biology expertise, has appointed Dr Alfredo Zurlo as Chief Medical Officer.
Dr. Zurlo is an oncologist with many years clinical experience and a proven track record in the pharmaceutical and biotechnology industries. His last role was at Mologen AG where he was Chief Medical Officer and Member of the Executive Board. Previously Dr. Zurlo held various positions at Roche and Roche SA, including Senior International Medical Leader Director Oncology and Medical Director Oncology. Before that, he was a medical advisor for the European Organisation for the Research and Treatment of Cancer (EORTC). Dr. Zurlo completed his oncology and radio oncology training at the University of Rome.